NCT03972722Unknown2 期
An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.
详细描述
Open, uncontrolled, multi-center, phase II study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Willingness to participate in the clinical trial; completely understanding and knowing about the study and signing the ICF; willingness and capability to comply with the requirements of the study.
- •Female aged from 18 to 75 years (margin included).
- •Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1).
- •Recurrent or metastatic cervical cancer patients who progress after receiving≥ 1 chemotherapy or are resistant to chemotherapy.
- •Based on RECIST 1.1, at least one measurable lesions, i.e. an extranodal lesion ≥10 mm in the longest diameter of cross-sectional areas or a lymph node lesion ≥ 15 mm in the shortest diameter of cross-sectional areas in CT or MRI test.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- •Life expectancy ≥ 12 weeks.
- •Organ and hematopoietic function as defined below:
- •Hemoglobin (HGB) ≥ 90 g/L; White blood cell (WBC) ≥ 3 X 109/L; Absolute neutrophil count (ANC) ≥ 1.5 X 109/L; Platelets (PLT) ≥ 100 X 109/L; Total bilirubin≤ 1.5×upper limit of normal (ULN); AST and ALT ≤ 2.5×ULN or, for hepatic dysfunction due to liver metastases, ≤ 5×ULN; Serum creatinine (Cr) ≤ 1.5 X ULN or a creatinine clearance (CrCl) ≥ 50 mL/min; International normalized ratio (INR) or activated partial thromboplastin time (aPTT)≤1.5×ULN;
- •Female patients of childbearing potential should be willing to birth control after ICF signing, the course of the study, and 5 months after the last dose of study medication.
- •Patients must agree to provide either an archival tumor tissue sample or fresh biopsy sample for baseline biomarker tissue analyses, including staining for PD-L
- •If archival tissue is not available and the patient does not have biopsy-accessible tumor lesions, the patient will be excluded.
排除标准
- •Prior therapy with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137 or anti-CTLA-4 agent (including Ipilimumab or any other drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •Prior anti-tumor therapy,(including chemotherapy, targeted small molecule therapy , radiotherapy, immunotherapy, mAb therapy) , or treatment with investigational products having not been launched onto the market in China in other clinical trials within 4 weeks prior to the first dose.
- •A past history of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the investigational product.
- •Pregnancy or lactation.
- •Patients with any autoimmune disease and received systemic therapy within 2 years (i.e. corticosteroids or immunosuppressive medications) [i.e.,but not limited to, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included), patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll].
- •Subjects that requires systemic corticosteroids (dose equivalent to or above 10 mg prednisone daily) or other immunosuppressive medications within 14 days prior to enrollment or for the course of the study.
- •Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Having received a live vaccine within 4 weeks prior to the first dose of investigational drug.
- •Having received a live anti-tumor vaccine, or anti-tumor treatment with immunostimulation.
- •Serious medical illness, such as severe infections, uncontrollable diabetes mellitus, cardiovascular diseases (i.e., grade 3 or 4 congestive heart failure (New York Heart Association (NYHA)), ≥ grade 2 heart block, myocardial infarction, uncontrolled arrhythmias, or unstable angina within 6 months prior to screening, and cerebral infarction within 3 months prior to screening) or lung diseases (i.e. interstitial pneumonia, obstructive pulmonary disease and symptomatic bronchospasm).
- •Patients with positive HBsAg and/or positive HBcAb with positive hepatitis B virus DNA> 103 copies/mL, or positive hepatitis C virus antibody; or positive syphilis.
- •A known history of human immunodeficiency virus (HIV) infection, or other acquired and congenital immune deficiency diseases.
- •A known history of active tuberculosis within 1 year prior to the first dose of investigational drug.
- •Presence of other malignant cancers within 5 years prior to enrollment. Patients with cured carcinoma in situ and cured skin basal cell carcinoma or cutaneous squamous cell carcinoma are eligible.
- •Having undergone allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
- •Having undergone major surgery (with the exception of baseline tumor biopsy), or serious trauma within 4 weeks prior to the first dose of therapy.
- •A history of alcoholism or drug abuse within 1 year.
- •A clear history of neurological or mental disorders, i.e. epilepsy, dementia, and poor compliance
- •Patients with other severe, acute or chronic disease that might increase risk of study drug use and participation, or laboratory abnormality that might confound the results of the trial.
- •Subjects not eligible for the study for other reasons, evaluated by the investigator.
研究组 & 干预措施
GLS-010
Experimental
Full-human anti-pd-1 monoclonal antibodies
干预措施: GLS-010 (Drug)
结局指标
主要结局
Objective response rate
时间窗: within 27 Months after patient enrolled
Based on an independent image assessment board
次要结局
- DCR(within 27 Months after patient enrolled)
- TTR(within 27 Months after patient enrolled)
- PFS(within 27 Months after patient enrolled)
- DOR(within 27 Months after patient enrolled)
- OS(within 3 years after patient enrolled.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical CancerCervical CancerNCT06039891Peking Union Medical College Hospital55
Unknown
2 期
Immunotherapy of Cervical Cancer With V3-CervixCervical CancerNCT03550755Immunitor LLC20
已完成
2 期
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical CancerCervical CancerStage IV Cervical Cancer FIGO 2018Adenosquamous Carcinoma of CervixMetastasisNCT05021237University of Texas Southwestern Medical Center12
进行中（未招募）
2 期
A Study of Anti-IL-6R mAb Injection in Patients With iMCDNCT05345522Beijing VDJBio Co., LTD.25
已完成
1 期
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, PaclitaxelNCT05529667Yonsei University15